Therapeutic Delivery of Pip4k2c‐Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart-Reference-Cited by-同舟云学术

Therapeutic Delivery of Pip4k2c‐Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart

Published:2021-03-12 Issue:10 Volume:8 Page:2004661
ISSN:2198-3844
Container-title:Advanced Science
language:en
Short-container-title:Adv. Sci.

Author:

Magadum Ajit¹²³,Singh Neha¹²³,Kurian Ann Anu¹²³,Sharkar Mohammad Tofael Kabir¹²³,Sultana Nishat¹²³,Chepurko Elena¹²³,Kaur Keerat¹²³,Żak Magdalena M.¹²³,Hadas Yoav¹²³,Lebeche Djamel¹,Sahoo Susmita¹,Hajjar Roger⁴,Zangi Lior¹²³^ORCID

Affiliation:

1. Cardiovascular Research Center Icahn School of Medicine at Mount Sinai New York NY 10029 USA

2. Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York NY 10029 USA

3. Black Family Stem Cell Institute Icahn School of Medicine at Mount Sinai New York NY 10029 USA

4. Phospholamban Foundation Amsterdam The Netherlands

Funder

National Heart, Lung, and Blood Institute

Publisher

Wiley

Subject

General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.202004661

Reference59 articles.

1. Heart Disease and Stroke Statistics—2014 Update

2. Dilated cardiomyopathy

3. Heart failure post-myocardial infarction: a review of the issues

4. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

5. A long noncoding RNA protects the heart from pathological hypertrophy

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy;Journal of Controlled Release;2024-08

2. Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration;Journal of Controlled Release;2024-05

3. Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics;Advanced Drug Delivery Reviews;2024-05

4. Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA Drug-Induced Cardiotoxicity Rank;Journal of Chemical Information and Modeling;2024-02-01

5. Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration;Journal of Cardiovascular Development and Disease;2024-01-26